Introduction
============

Cervical cancer is the fourth most common cancer type among females worldwide, with \>500,000 new cases diagnosed in 2018; 11,000 patients are diagnosed and \~3,000 patients die annually in Japan ([@b1-ol-0-0-11899],[@b2-ol-0-0-11899]). Although squamous cell carcinoma continues to be the most frequent pathological type, the incidence of cervical adenocarcinoma (AC) and adenosquamous carcinoma (ASC) has increased in several countries ([@b3-ol-0-0-11899]--[@b5-ol-0-0-11899]). AC and ASC of the uterine cervix accounted for 15--25% of all cases of cervical cancer ([@b3-ol-0-0-11899],[@b5-ol-0-0-11899]) and the affected patients were younger than those with squamous cell carcinoma (SCC) ([@b5-ol-0-0-11899]).

The prognosis of patients with AC and ASC has been evaluated in several studies, but the results remain controversial ([@b6-ol-0-0-11899]--[@b18-ol-0-0-11899]). Certain studies have indicated that the prognosis of AC and ASC is worse than that of SCC, while others reported a similar prognosis. In addition, AC and ASC are less radiosensitive than SCC ([@b16-ol-0-0-11899],[@b19-ol-0-0-11899]). Hence, it remains elusive whether the treatment strategy used for SCC may be adopted for patients with AC and ASC. Therefore, the factors associated with the prognosis of AC and ASC and the biomarkers targetable with molecular targeted drugs require investigation.

Erb-b2 receptor tyrosine kinase 3 (HER3) is a member of the epidermal growth factor receptor (EGFR) family and is a cell-surface receptor tyrosine kinase ([@b20-ol-0-0-11899]). HER3 overexpression is associated with unfavorable prognosis in several cancer types ([@b21-ol-0-0-11899]). Although the incidence of HER3 overexpression ranged from 55.6 to 74.4% among cases of SCC of the cervix and HER3 was indicated to be a poor prognostic factor, information regarding the expression of HER3 in cases of AC and ASC of the cervix and whether it is a prognostic factor remains limited ([@b22-ol-0-0-11899],[@b23-ol-0-0-11899]). Therefore, the present study aimed to evaluate the expression of HER3 and its significance in the post-operative recurrence in patients with AC and ASC of the cervix.

Patients and methods
====================

### Patients and specimens

The medical records of patients with cervical cancer who were diagnosed and treated at the National Cancer Center Hospital (Tokyo, Japan), between January 1997 and December 2017 were retrospectively analyzed. Patients included in the present study fulfilled the following inclusion criteria: i) Pathological diagnosis of AC and ASC of the cervix, ii) early-stage disease \[International Federation of Gynecology and Obstetrics (FIGO) stages I and II\] and iii) availability of sufficient formalin-fixed paraffin-embedded surgical specimens for immunohistochemical staining and analysis ([@b24-ol-0-0-11899]).

Specimens of 39 cases of AC (n=27) and ASC (n=12) of the cervix obtained via surgical resection were retrieved from the pathology database of the National Cancer Center Hospital (Tokyo, Japan). The histological type was based on the World Health Organization classification of tumors of the uterine cervix (4th edition) ([@b25-ol-0-0-11899]). The medical records of all the identified patients were evaluated to obtain the following information: Age, performance status at diagnosis, FIGO clinical stage, date of treatment initiation, date of surgery, date of radiotherapy, the administered chemotherapy regimen, date of progression, date of the last follow-up and survival status. The protocol for the human study was reviewed and approved by the ethics committee of the National Cancer Center Hospital (Tokyo, Japan; no. 2014-393). Written informed consent was obtained from all of the participants.

### Immunohistochemical staining and analysis

Hematoxylin and eosin (H&E)-stained slides from each of the cases were reviewed to obtain representative sections. New 4-µm-thick sections were prepared from formalin-fixed paraffin-embedded surgical specimens and were immunohistochemically stained. After deparaffinization, the expression of HER3 was determined by immunohistochemistry using a rabbit monoclonal antibody against HER3 (1:59 dilution; clone D22C5; Cell Signaling Technology, Inc.). Antigen retrieval was achieved by using a PT Link machine (Dako) at high pH. Immunohistochemistry staining was performed using the Dako autostainer Link48 (Dako) and EnVision Flex Mini kit (Dako), according to the manufacturer\'s protocols. The slides were counterstained with hematoxylin.

HER3 expression was evaluated by an experienced pathologist in accordance with the HER2 testing guidelines for gastroesophageal cancer from the College of American Pathologists, American Society for Clinical Pathology and American Society of Clinical Oncology ([@b26-ol-0-0-11899]). High HER3 expression (HER3-high) was defined as a score of 2+ or 3+ and low HER3 expression (HER3-low) was defined as a score of 0 or 1+. Immunohistochemical staining of p16 (clone INK4, 1;10, BD Bioscience) was also performed for the representative tumor section of each case. The slides were evaluated by the pathologist with the cut-off for positivity \>70%. The pathologist was blinded to the clinical data while evaluating the slides.

### Statistical analysis

Disease-free survival (DFS) was defined as the time between the date of initial surgery to the date of documentation of relapse, including locoregional recurrence and/or distant metastasis or death from any cause. The absence of relapse or death was treated as a censored observation. Overall survival (OS) was defined as the time from the date of initial surgery to the date of death from any cause. Patients without such events were treated as censored observations. DFS and OS were estimated using the Kaplan-Meier method and survival curves were compared using the log-rank test. A possible influence of HER3 expression on survival was assessed by using univariate and multivariate Cox regression analyses with the forced entry method after adjustment for established risk factors of post-operative recurrence ([@b27-ol-0-0-11899]--[@b29-ol-0-0-11899]). A two-sided P\<0.05 was considered to indicate statistical significance. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University) ([@b30-ol-0-0-11899]), which is a graphical user interface for R (The R Foundation for Statistical Computing).

Results
=======

### Patient characteristics

Of the 39 patients with stages Ib1-IIB included in the present study, 27 were histologically classified as AC and 12 as ASC. The demographic and clinicopathological characteristics of the patients are summarized in [Table I](#tI-ol-0-0-11899){ref-type="table"}. The study population included 39 patients with an age range of 32 to 67 years. The median age of the patients was 43 years. The clinical stage of the patients determined according to the FIGO staging system was stage IB1 in 25 patients, IB2 in 9 and IIB in 4 patients. Lymph node metastasis was present in 38.5% of patients. Expression of p16 was positive in 79.8% (31/39) of all cases, 70.4% (19/27) of cases of AC and 100.0% (12/12) of cases of ASC.

### Immunohistochemistry staining for HER3 expression in AC and ACC of the cervix

HER3 expression was determined in the surgical specimens from 39 patients with AC and ASC of the cervix using immunohistochemistry. Membranous HER3 overexpression was evaluated according to the criteria described above and representative images are provided in [Fig. 1](#f1-ol-0-0-11899){ref-type="fig"}. High expression of HER3 (HER3-high) was determined in 85.1% (23/27) of cases of AC and in 58.3% (7/12) of cases of ASC ([Table II](#tII-ol-0-0-11899){ref-type="table"}).

### Association of HER3 expression with outcomes

During the median follow-up of 63.1 months, the 5-year DFS rates in patients with AC and ASC of the cervix were 56.7% among patients with HER3-high and 77.8% among patients with HER3-low (log-rank P=0.20; [Fig 2A](#f2-ol-0-0-11899){ref-type="fig"}). The 5-year OS rates were 83.3% among patients with HER3-high and 100.0% among patients with HER3-low (log-rank P=0.22; [Fig 2B](#f2-ol-0-0-11899){ref-type="fig"}). Multivariate logistic regression analysis with the Cox proportional hazards model revealed that HER3-high \[hazard ratio (HR)=6.32, 95% CI: 1.10--36.26, P=0.039), pelvic lymph node metastasis (HR=7.61, 95% CI: 2.07--28.00, P=0.002) and vascular invasion (HR=4.28, 95% CI: 1.12--16.31, P=0.033) were independent prognostic factors regarding DFS ([Table III](#tIII-ol-0-0-11899){ref-type="table"}).

Discussion
==========

The results of the present study suggested an association between the clinical outcomes of early-stage AC and ASC of the cervix and HER3 expression. Although HER3 expression did not exhibit any statistical significance on univariate Cox analysis for DFS, HER3 was a significant predictor on multivariate Cox analysis, indicating unfavorable DFS and OS prognosis. To the best of our knowledge, the present study was so far the largest to evaluate the expression of HER3 and its significance on post-operative recurrence in patients with early-stage AC and ASC of the cervix.

HER3 is overexpressed in several cancer types and is associated with poor prognosis ([@b20-ol-0-0-11899],[@b31-ol-0-0-11899]--[@b38-ol-0-0-11899]). HER3 promotes tumor initiation and progression, mainly through heterodimerization with receptor tyrosine kinases, to activate oncogenic signaling via the PI3K/AKT pathway. In addition, HER3 expression and downstream PI3K/AKT signaling are major causes of treatment failure in cancer therapy due to their implication in therapeutic resistance ([@b39-ol-0-0-11899]). In the present study, HER3 expression was not a prognostic factor in the univariate Cox regression for DFS, on the other hand, HER3 overexpression appeared to be a poor prognostic factor for DFS in the multivariate Cox regression, along with pelvic lymph node metastasis and vascular invasion. This discrepancy between univariate and multivariate results can be attributed to the small number of cases and the resulting instability of the prognostic model. These results are still consistent with those of previous studies on patients with cervical cancer with SCC, in which HER3 was overexpressed in 74.4% (58/78) of patients and was associated with poor prognosis ([@b22-ol-0-0-11899]). In a study by Lee *et al* ([@b23-ol-0-0-11899]), 55 patients with FIGO IB-IVA cervical cancer, including 5 patients with AC and 2 with ASC, were evaluated for the expression of HER and phosphorylated AKT. However, the incidence of HER3 overexpression and its influence on survival among those populations were not presented, thereby remaining elusive. Therefore, the present study was the first to demonstrate the prognostic value of HER3 overexpression among patients with cervical AC and ASC. Due to the aforementioned discrepancy between the univariate and multivariate Cox regression model, the prognostic value of HER3 should be further verified in future studies. Combining the results of the present study with those obtained in previous studies, the incidence of HER3 overexpression was 55.6--74.4% in patients with SCC, 85.1% in patients with AC and 58.3% in patients with ASC ([@b22-ol-0-0-11899],[@b23-ol-0-0-11899]). Whole-exome sequencing of primary frozen tumor tissues and the blood of patients with cervical cancer who did not receive any prior chemotherapy or radiotherapy indicated that the incidence of HER3 alterations was higher in patients with AC than in those with SCC ([@b40-ol-0-0-11899]). Several targeted therapies have been developed for HER3 and relevant studies indicate a possible therapeutic strategy for patients with cervical cancer expressing HER3 ([@b41-ol-0-0-11899],[@b42-ol-0-0-11899]).

Surgery and/or radiotherapy are highly effective for early-stage cervical cancer. However, patients with AC and ASC of the cervix are more resistant to radiotherapy than those with SCC ([@b16-ol-0-0-11899],[@b19-ol-0-0-11899]); therefore, novel therapies are required for patients with AC and ASC of the cervix. Recently, combination therapy with a dual antibody targeting both EGFR and HER3 and enhanced ionizing radiation was reported to be effective ([@b43-ol-0-0-11899]). An additive effect was observed when the dual antibody, radiation and cisplatin were combined, leading to improved patient outcomes by increasing tumor control and by activating the immune response.

The human papillomavirus (HPV) is a carcinogenic virus in humans and has been implicated in cervical cancer ([@b44-ol-0-0-11899]). Among head and neck cancers, HER3 was overexpressed and highly bound to PI3K in HPV-positive tumors ([@b45-ol-0-0-11899]). In addition, a preclinical study by Brand *et al* ([@b46-ol-0-0-11899]) reported an association between HPV infection and HER3 in head and neck cancers, indicating that HPV-positive cancers were sensitive to HER3 targeting. By contrast, no association has been detected between HPV infection and HER in patients with cervical cancer. In the population included in the present study, the incidence of both HER3 and p16 expression was high and the correlation was not significant (data not shown). Accordingly, further studies are required to evaluate the etiology of HPV infection and HER3 expression in patients with cervical cancer.

The present study has several limitations; it was a retrospective study in a single institution and included a small number of patients with AC and ASC in the cervix. In addition, as the enrollement period was long, the treatment strategy varied over the decades. Hence, further study is required to evaluate the role of HER3 in the current era of precision medicine, during which several HER3-targeting drugs are being developed ([@b47-ol-0-0-11899]--[@b49-ol-0-0-11899]). In the present study, the DFS of patients who underwent surgery was evaluated, which is an important factor for such patients; however, the influence of HER3 on OS remains undetermined due to the small number of patients who died. Furthermore, even though most of the study population was positive for p16, no significant correlation between p16 and HER3 was determined. Accordingly, future studies are required to determine the etiology of HPV infection and HER3 expression in patients with cervical cancer.

In conclusion, the results of the present study indicated that the expression of HER3 was associated with poor DFS in patients with early-stage AC and ASC of the cervix; therefore, HER3 expression may be a novel prognostic biomarker. However, further studies are required to confirm these results and the prognostic value of HER3.
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![Representative histology images. (A) H&E staining. (B-D) Immunohistochemical staining for HER3; (B) endocervical adenocarcinoma, usual type, pT1bN0, with HER3 score of 1+; (C) endocervical adenocarcinoma, usual type, pT2bN1, HER3 score of 2+; (D) endocervical adenocarcinoma, usual type, pT2bN1, HER3 score of 3+ (original magnification of all the histological images, ×200). HER3 was predominantly expressed in the cytoplasm and on the membranes of tumor cells. HER3, Erb-b2 receptor tyrosine kinase 3; H&E, hematoxylin and eosin.](ol-20-04-11899-g00){#f1-ol-0-0-11899}

![Kaplan-Meier curves for disease-free survival and overall survival depending on the status of HER3 expression. Kaplan-Meier curves for (A) disease-free survival and (B) overall survival of patients with metastatic disease with high HER3 expression (dashed line) and low HER3 expression (solid line). HER3, Erb-b2 receptor tyrosine kinase 3.](ol-20-04-11899-g01){#f2-ol-0-0-11899}

###### 

Patient characteristics.

                                      HER3 expression                   
  ----------------------------------- ----------------- --------------- -------
  Age (years)                         42.5 (30--67)     46.0 (40--64)   0.384
  FIGO stage (2014)                                                     0.216
    IB1                               20 (66.6)         5 (55.5)        
    IB2                               8 (26.6)          2 (22.2)        
    IIB                               2 (6.6)           2 (22.2)        
  Histological type                                                     0.066
    Adenocarcinoma                    23 (76.6)         4 (44.4)        
    Adenosquamous carcinoma           7 (23.3)          5 (55.5)        
  Parametrial invasion                                                  0.311
    Present                           8 (26.7)          4 (44.4)        
    Absent                            22 (73.3)         5 (55.5)        
  Vascular invasion                                                     0.134
    0                                 13 (43.3)         3 (33.3)        
    1                                 13 (43.3)         5 (55.5)        
    2                                 3 (10.0)          1 (11.1)        
    3                                 1 (3.3)           0 (0.0)         
  Tumor size (cm)                                                       0.379
    ≤4                                15 (50.0)         6 (66.6)        
    \>4                               15 (50.0)         3 (3.33)        
  Lymph node metastases                                                 0.047
    Present                           21 (70.0)         3 (33.3)        
    Absent                            9 (30.0)          6 (66.6)        
  Treatment                                                             0.145
    Surgery alone                     15 (50.0)         3 (33.3)        
    Surgery + adjuvant radiation      13 (43.3)         5 (55.5)        
  Surgery + adjuvant chemoradiation   2 (6.6)           1 (11.1)        

Values are expressed as the median (range) or n (%). FIGO, International Federation of Gynecology and Obstetrics; HER3, Erb-b2 receptor tyrosine kinase 3.

###### 

Expression score of HER3 in cervical adenocarcinoma and adenosquamous carcinoma.

  Histological type         N    0         1+         2+          3+          2+/3+
  ------------------------- ---- --------- ---------- ----------- ----------- -----------
  Adenocarcinoma            27   0 (0.0)   4 (14.8)   12 (44.4)   11 (40.7)   23 (85.1)
  Adenosquamous carcinoma   12   0 (0.0)   5 (41.7)   4 (33.3)    3 (25.0)    7 (58.3)
  Total                     39   0 (0.0)   9 (23.1)   16 (41.0)   14 (35.9)   30 (76.9)

Values are expressed as n (%). HER3, Erb-b2 receptor tyrosine kinase 3.

###### 

Univariate and multivariate analysis of prognostic factors for disease-free survival.

                                                      Univariate                 Multivariate                        
  --------------------------------------------------- ------------ ------------- -------------- ------ ------------- -------
  HER3 (high vs. low)                                 2.54         0.57--11.31   0.220          6.32   1.10--36.26   0.039
  Pelvic lymph node metastasis (present vs. absent)   3.17         1.12--8.98    0.030          7.61   2.07--28.00   0.002
  Tumor size (≥4 vs. \<4 cm)                          1.67         0.60--4.63    0.322          1.05   0.30--3.69    0.942
  Vascular invasion (present vs. absent)              3.28         1.04--10.39   0.043          4.28   1.12--16.31   0.033
  Parametrial invasion (present vs. absent)           1.62         0.58--4.57    0.361          0.68   0.18--2.59    0.570

HR, hazard ratio; HER3, Erb-b2 receptor tyrosine kinase 3.
